Stability Biologics, LLC - Purchase Price Allocation (Details) - USD ($)	Jan. 13, 2016	Jan. 01, 2015	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Cash paid at closing	$ 6,000,000
Working capital adjustment	(481,000)
Common stock issued (441,009 shares)	3,347,000
Fair value of earn-out	17,450,000
Total fair value of purchase price	28,087,000
Net assets acquired:
Other long-term assets	199,000
Property, plant and equipment	1,375,000
Deferred tax liability	(5,896,000)
Subtotal	(1,866,000)
Intangible assets	13,790,000
Goodwill	16,163,000		$ 19,976,000	$ 19,976,000	$ 20,200,000	$ 20,203,000
Total assets purchased	28,087,000
Working capital and other assets were composed of the following (in thousands):
Cash	140,000
Prepaid Expenses and other current assets	100,000
Accounts receivable	2,001,000
Federal and state taxes receivable	28,000
Inventory	9,002,000
Accounts payable and accrued expenses	(8,815,000)
Debt-free working capital	2,456,000
Current portion of long-term debt	(194,000)
Long-term debt	(560,000)
Line of Credit	(932,000)
Shareholder loan	(85,000)
Assumed debt	(1,771,000)
Net working capital	685,000
Stability Biologics, LLC
Business Acquisition [Line Items]
Cash paid at closing	6,000,000.0
Common stock issued (441,009 shares)	$ 3,347,000
Equity issued for acquisition (shares)	441,009.000	441,009
Fair value of earn-out	$ 17,500,000
Working capital and other assets were composed of the following (in thousands):
Long-term debt	(1,800,000)
Customer relationships
Net assets acquired:
Intangible assets	5,330,000
Patents and know how
Net assets acquired:
Intangible assets	6,790,000
Trade names and trademarks
Net assets acquired:
Intangible assets	450,000
Non-compete agreements
Net assets acquired:
Intangible assets	830,000
Licenses and permits
Net assets acquired:
Intangible assets	$ 390,000